BioLineRx outlines Phase 1/2a GLIX1 trial in recurrent high-grade glioma at EANO 2026
BLRX•GLIX1 abstracts set for EANO 2026
- BioLineRx set two GLIX1 abstracts for EANO 2026, including preclinical efficacy data in glioblastoma models.
- Results will be presented September 25, 2026; the company framed the studies as showing strong anti-tumor activity and a survival benefit.
First-in-human trial in recurrent high-grade glioma
- A separate e-poster outlines an actively enrolling first-in-human Phase 1/2a trial in recurrent or progressive high-grade glioma.
- The program targets a high-need brain cancer market; upcoming conference readouts could shape investor expectations for early clinical traction.
